Arjo Ab Class B · OMXSTO:ARJO_B
Arjo Ab Class B — Q3 2025 Earnings Presentation
14 slides from Arjo Ab Class B's earnings presentation, Oct 22, 2025
Slide 1: Healthy demand and higher growth
ARJO Q3 REPORT 2025 Healthy demand and higher growth Niclas Sjöswärd, Interim CEO Christofer Carlsson, CFO 1
Slide 2: Growth across most markets
Growth across most markets Net sales Gross • Healthy demand across most markets organic growth margin • Growth held back by continued weaker development in the UK, as well as lower Diagnostics sales in the quarter 3.8% 41.1% • Currency effects, US tariffs and geographic mix weighs on gross profit Ad
Slide 3: Sales development by region
3.0% 5.7% North America Global Sales Continued growth in the US Western Europe, +2.1% • Continued good traction in • Strong development across several Patient handling & service large markets incl. France and Germany • Challenging market in the UK Canada continues growth streak Rest of the World, +1
Slide 4: Gross margin somewhat lower y-o-y
Gross profit bridge – Q3 2025 vs. Q3 2024 (MSEK) Gross margin somewhat lower y-o-y x Margin (Percent) x Margin development (Percentage point) • Unfavorable mix effects from product and 42.0% N/A -0.6 p.p. -0.3 p.p. 41.1% geography with significant increase in medical beds sales in RoW • Significant
Slide 5: Underlying trend remains positive
Adj. EBIT bridge – Q3 2025 vs. Q3 2024 (MSEK) Underlying trend remains positive x Margin (Percent) 6.0% 6.2% • Adj. EBIT margin increasing vs. Q3 2024 -8 10 15 -17 • Stable underlying business – excluding effects of currencies and tariffs, the adjusted operating profit increased over 20% 164 165 • O
Slide 6: Q3 working capital and operating cash flow
Q3 working capital and operating cash flow Decrease in working capital days Operating cash flow above target conversion in Q3 Working capital days – Q1.23-Q3.25 Operating cash flow – Q1.23-Q3.25 Operating cash flow (MSEK)* Working capital days* 734 565 96 95 512 479 86 437 446 82 84 83 82 79 78 81 7
Slide 7: Q3 net debt and leverage
Q3 net debt and leverage Net debt decrease in Q3 in line with historical trend Decrease in Leverage vs Q2, on par with LY Net debt – Q1.23-Q3.25 Leverage – Q1.23-Q3.25 Net debt, incl. IFRS16 (BSEK) Net debt / Adj EBITDA, multiple (R12)* 5.3 5.2 2.8 2.8 4.7 2.6 4.7 2.4 4.5 4.5 2.3 2.3 2.3 4.3 4.4 4.4
Slide 8: Other business highlights
Other business highlights • US FDA 510(k) approval for fetal monitors • Two small recent acquisitions Arden (AUS) and Slingcare (NL) to contribute positively from Q4 2025 • Arjo upgraded to highest ESG rating – AAA – by MSCI • Andréas Elgaard appointed new President & CEO – to assume his position on
Slide 9: Outlook
Outlook 2025 Organic net sales growth for 2025 is expected to be within the Group’s target interval of 3-5% 9 9
Slide 10: Summary
Higher growth Positive rate in Q3 vs. first underlying half of the year profitability development Summary On track towards Improving cash 3-5% organic net flow and cash sales growth conversion in 2025 10
Slide 11: Q&A
Q&A 11
Slide 12: Financial calendar / Further questions
Financial calendar Year-end Report 2025 January 30, 2026 Annual and Sustainability Report 2025 March-April 2026 Interim Report Jan-Mar 2026 April 29, 2026 Annual General Meeting 2026 April 29, 2026 Further questions Maria Nilsson EVP, Communication & Public Relations +46 734 244 515 maria.nilsson@ar
Slide 13: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of Arjo’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will
Slide 14: aifJjJoO
aifJjJoO EMPOWERING MOVEMENT